JNJ-81201887基因治疗继发于年龄相关性黄斑地图样萎缩的1期研究
这项1期开放标签单中心首次人体研究纳入17例继发于AMD的地图样萎缩患者,按低、中、高剂量单次玻璃体内注射JNJ-81201887,评估24个月安全性与耐受性。结果显示各剂量组耐受良好,无剂量限制性不良事件,5例(29%)出现治疗相关轻度眼内炎症,高剂量组地图样萎缩病灶增长速率持续下降。
要点
- JNJ-81201887单次玻璃体内注射在3个剂量组均耐受良好,无剂量限制性不良事件。
- 5/17例(29%)发生治疗相关轻度眼内炎症,4/5例经局部激素或观察后缓解。
- 高剂量组治疗眼地图样萎缩病灶增长速率24个月内持续下降。
核心结论
- JNJ-81201887的3个研究剂量在24个月随访中均显示可控的安全性特征。
- 作者认为有必要对JNJ-81201887治疗地图样萎缩开展进一步研究。
研究设计与样本
- 1期、开放标签、单中心、首次人体临床研究。
- 纳入17例年龄≥50岁、继发于AMD的地图样萎缩患者,治疗眼Snellen最佳矫正视力≤20/200(前3例后为≤20/80),地图样萎缩病灶总面积5-20 mm²(2-8个视盘面积),对侧非治疗眼最佳矫正视力≥20/800。
- 患者序贯入组低剂量(3.56×10¹⁰病毒基因组/眼;n=3)、中剂量(1.07×10¹¹病毒基因组/眼;n=3)和高剂量(3.56×10¹¹病毒基因组/眼;n=11)队列,无激素预防,评估24个月安全性与耐受性。
主要发现
- 所有入组患者均表现为中心凹中心受累的地图样萎缩。
- JNJ-81201887在各队列均耐受良好,无剂量限制性不良事件,未发生与研究干预相关的严重或全身性不良事件。
- 17例中5例(29%)经历5次与研究治疗相关的轻度眼内炎症事件,所有检查发现均消退,5例中4例经局部激素或观察后不良事件消退。
- 1例患者发生1次未消退的玻璃体炎事件,予观察处理,该患者同时发生1次无关的致死性不良事件。
- 未报告眼内炎或新发脉络膜新生血管。
关键数值与推荐
- 各队列24个月期间地图样萎缩病灶增长速率相似。
- 高剂量组治疗眼地图样萎缩病灶增长速率在24个月内持续下降,平均平方根病灶增长从0-6个月的0.211 mm降至18-24个月的0.056 mm。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and tolerability of a single intravitreal injection of JNJ-81201887 (JNJ-1887) in patients with geographic atrophy (GA) secondary to advanced dry age-related macular degeneration (AMD). DESIGN: Phase 1, open-label, single-center, first-in-human clinical study. PARTICIPANTS: Adult patients (≥50 years of age) with GA secondary to AMD in the study-treated eye (treated eye) with Snellen best-corrected visual acuity of 20/200 or worse in the treated eye (20/80 or worse after the first 3 patients), a total GA lesion size between 5 and 20 mm2 (2-8 disc area), and best-corrected visual acuity of 20/800 or better in fellow, nontreated eye were included. METHODS: Patients (n = 17) were enrolled sequentially into low-dose (3.56 × 1010 viral genome/eye; n = 3), intermediate-dose (1.07 × 1011 viral genome/eye; n = 3), and high-dose (3.56 × 1011 viral genome/eye; n = 11) cohorts without steroid prophylaxis and assessed for safety and tolerability over 24 months. MAIN OUTCOME MEASURES: Safety and tolerability outcomes included assessment of ocular and nonocular treatment-emergent adverse events (AEs) over 24 months. Secondary outcomes included GA lesion size and growth rate. RESULTS: Baseline patient characteristics were consistent with the disease under study, and all enrolled patients demonstrated foveal center-involved GA. JNJ-81201887 was well-tolerated across all cohorts, with no dose-limiting AEs. No serious or systemic AEs related to study intervention occurred. Overall, 5 of 17 patients (29%) experienced 5 events of mild ocular inflammation related to study treatment; examination findings in all resolved, and AEs resolved in 4 of 5 patients after topical steroids or observation. One unresolved vitritis event, managed with observation, occurred in a patient with an unrelated fatal AE. No endophthalmitis or new-onset choroidal neovascularization was reported. Geographic atrophy lesion growth rate was similar among all cohorts over 24 months. For treated eyes in the high-dose cohort, GA lesion growth rate showed continued decline through 24 months, with a reduction in mean square root lesion growth from 0.211 mm at months 0 through 6 to 0.056 mm at months 18 through 24. CONCLUSIONS: All 3 studied doses of JNJ-1887 showed a manageable safety profile through 24 months of follow-up. Further investigation of JNJ-1887 for the treatment of GA is warranted. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Heier JS, Cohen MN, Chao DL, et al. Phase 1 Study of JNJ-81201887 Gene Therapy in Geographic Atrophy Secondary to Age-Related Macular Degeneration. Ophthalmology. 2024. PMID: 38909914. doi:10.1016/j.ophtha.2024.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。